Navigation Links
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
Date:11/1/2011

study published in the August 2011 issue of the journal Gastroenterology showed that LX1031 was well tolerated and provided clinical benefit to patients with non-constipating IBS, showing improvements in a global assessment of adequate relief from IBS pain and discomfort and in stool consistency, with symptom relief correlating with reductions in the 5-HIAA biomarker.  Like LX1031, LX1033 acts locally in the gastrointestinal tract to reduce serotonin production by inhibiting tryptophan hydroxylase, a key enzyme in the biosynthesis of serotonin.  
  • LX2931:  Lexicon initiated a dose-ranging study to explore higher doses of LX2931 in rheumatoid arthritis patients.  Previously-reported Phase 2a results of LX2931, an inhibitor of sphingosine-1-phosphate lyase, demonstrated a favorable safety profile at all doses tested and suggest that rheumatoid arthritis patients treated with 150 mg of LX2931 once daily showed improvement in the primary efficacy endpoint of the study, the percentage of patients achieving an American College of Rheumatology 20 (ACR20) response at week 12.

  • Financial Results Revenues:  Lexicon's revenues for the three months ended September 30, 2011 decreased 55 percent to $0.4 million from $0.8 million for the corresponding period in 2010.  For the nine months ended September 30, 2011, revenues decreased 59 percent to $1.5 million from $3.7 million for the corresponding period in 2010.

    Research and Development Expenses:  Research and development expenses for the three months ended September 30, 2011 increased 4 percent to $19.7 million from $18.9 million for the corresponding period in 2010, primarily due to an increase in external preclinical and clinical research and development costs, offset by a decrease in personnel costs.  For the nine months ended September 30, 2011, research and develop
    '/>"/>

    SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
    2. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
    3. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
    4. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
    5. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
    6. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
    7. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
    8. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
    9. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
    10. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
    11. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/31/2015)... -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ("Galmed"), ... and commercialization of a once-daily, oral therapy for ... today announced financial results for the 12 months ... 2014 Highlights: , Hosted a key opinion ... Rohit Loomba, MD, MHSc., who discussed the topic ...
    (Date:3/31/2015)... , March 31, 2015  CVS Health (NYSE: ... into new clinical affiliations with Rush University Medical ... and Tucson Medical Center in Tucson, ... Arizona Connected Care. These affiliations will help enhance ... patients. Through these clinical affiliations, CVS Health will ...
    (Date:3/31/2015)... , March 31, 2015  Oxis International, Inc. (OXIS) ... development and commercialization, announced today Oxis CEO Tony ... of Oxis common shares on the Euronext exchange. Oxis ... the symbol OXIS.   Oxis Chairman and ... to move forward with its strategies launched in 2014 ...
    Breaking Medicine Technology:Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 3Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 4Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 5Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 6Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 7Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 8CVS Health Announces New Clinical Affiliations with Leading Medical Centers in Arizona and Illinois 2CVS Health Announces New Clinical Affiliations with Leading Medical Centers in Arizona and Illinois 3Oxis International Inc. Announces Request for Euronext Trading Suspension 2
    ... Mich., and GERMANTOWN, Md., Nov. 21, 2011 Adeona ... a developer of innovative disease-modifying medicines for serious ... Corporation, a synthetic biology company that utilizes its ... announced today the formation of a global exclusive ...
    ... 18, 2011 Breast cancer patients, their families and ... Administration (FDA) decision to remove the anti-cancer drug Avastin ... stage breast cancer. Terry Kalley, founder of ... condemned the decision, saying, "While this vote is highly ...
    Cached Medicine Technology:Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension 2Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension 3Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension 4Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension 5Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension 6Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension 7
    (Date:3/31/2015)... 2015 OnChip Devices , a world ... silicon ESD diode chip targeted towards low voltage LED applications. ... Zeners are ideal for protecting circuits by suppressing voltage higher ... handle pulses of up to 350W and 20A, providing protection ... 61000-4-2 standard. These diodes do not exhibit any device ...
    (Date:3/31/2015)... Clinovo, a leading provider of cloud-based ... the premiere voice of Northern California’s Life Science ... , BayBio brings together the collective strength ... productive life science cluster, helping companies grow, connect ... pressing challenges. , “We are thrilled to ...
    (Date:3/31/2015)... (PRWEB) March 31, 2015 At Summit Breast ... all patients in a calm and caring manner. , Summit ... diagnosis and surgical treatment of breast cancer. They treat ... but from all over the world. Their doctors continue ... publications. , The seeds for Summit Breast Care were planted ...
    (Date:3/31/2015)... 2015 Beckman Coulter is sponsoring a ... “Subvisible Particulate Matter in Therapeutic Protein Injections”,” an educational session ... in counting particles in liquids, with a focus on the ... free to attend and will be broadcast live April 8, ... new test for protein-based materials, known as USP 787 ...
    (Date:3/31/2015)... 31, 2015 BESLER Consulting today ... “The Value of an Independent Cost Report Review.” ... a critical role in the determination of Medicare ... appropriate understanding and review, this report can assist ... planning. , This white paper discusses:, ...
    Breaking Medicine News(10 mins):Health News:OnChip Introduces Low Voltage Diodes for High-Brightness LED Protection 2Health News:Clinovo Joins BayBio Membership Program, The Leading Life Science Association in Northern California 2Health News:Summit Breast Care is Celebrating Four Years as "NJ Top Docs" 2Health News:Beckman Coulter Webinar Series Presents Insight into New Demands in Counting Particles in Liquids 2Health News:Beckman Coulter Webinar Series Presents Insight into New Demands in Counting Particles in Liquids 3
    ... Those with high levels of Epstein-Barr antibodies double their ... 7 (HealthDay News) -- Smoking appears to enhance the ... nearly doubling the chances of getting the disabling neurologic ... risk factor is having high levels of antibodies to ...
    ... Studying patients with kidney cancer, a team of researchers at ... a pair of proteins excreted in the urine that could ... The research, published online in the May issue of ... proteins secreted in urine that appear to accurately reveal the ...
    ... Henry Ford Hospital have found that infection with the ... cancer. Using administrative data from more than 67,000 ... the period 1997-2008, 0.6% (17/3057) patients with hepatitis C ... without the disease developed kidney cancer. After ...
    ... insight into patterns, coloring for species generally , WEDNESDAY, ... learned the long-sought-after secret of how animals make spots, ... a species of fruit fly ( Drosophila guttifera ) ... spots. Researchers found that morphogen -- a protein present ...
    ... drug might reverse genetic process that leads to disease, ... Researchers may have found an easy way to detect ... as well as a way to reverse the start ... drug. , "It,s incredibly, incredibly exciting," said Dr. ...
    ... levels of copper and iron to Alzheimer,s disease, heart disease, ... Chemical Research in Toxicology suggests specific steps that older ... of these metals in their bodies. "This story of copper ... of public health significance, is virtually unknown to the general ...
    Cached Medicine News:Health News:Smoking May Boost MS Risk in Some 2Health News:Smoking May Boost MS Risk in Some 3Health News:Urine test for kidney cancer a step closer to development 2Health News:Urine test for kidney cancer a step closer to development 3Health News:Henry Ford Hospital atudy: Hepatitis C infection doubles risk for kidney cancer 2Health News:Science Reveals Secrets of Animals' Spots, Stripes 2Health News:Simple Test May Spot Early Lung Cancer 2Health News:Simple Test May Spot Early Lung Cancer 3
    Inquire...
    ... the elegant and sophisticated woman, ... includes ophthalmic and sunwear styles. ... variety of shapes and colors, ... shapes and complexions. Many styles ...
    ... updated styling through the use of innovative ... collection is for the value driven consumer ... Eyewear Collection , The futuristic quality ... of the "strongest and lightest metal on ...
    Inquire...
    Medicine Products: